Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Follicular Lymphoma (FL)
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Kymriah
Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Multiple Sclerosis
Solid Tumors
Influenza
Chronic Obstructive Pulmonary Disease
Swine-Origin Influenza A H1N1 Virus